Inhibition of CysLT-induced bronchial smooth muscle contraction likely is involved in the therapeutic effects of these agents to relieve the symptoms of asthma.
Leukotriene-Synthesis Inhibitors The formation of leukotrienes depends on lipoxygenation of arachidonic acid by 5-lipoxygenase. Zileuton is a potent and selective inhibitor of 5-lipoxygenase activity and thus blocks the formation of all 5-lipoxygenase products. Thus, in addition to inhibiting the formation of the cys-LTs, zileuton also inhibits the formation of leukotriene B4 (LTB4), a potent chemotactic autacoid, and other eicosanoids that depend on leukotriene A4 (LTA4) synthesis. Logically, the therapeutic effects of a 5-lipoxygenase inhibitor would include all those observed with the CysLT-receptor antagonists, as well as other effects that may result from inhibiting the formation of LTB4 and other 5-lipoxygenase products.
Was this article helpful?
If you suffer with asthma, you will no doubt be familiar with the uncomfortable sensations as your bronchial tubes begin to narrow and your muscles around them start to tighten. A sticky mucus known as phlegm begins to produce and increase within your bronchial tubes and you begin to wheeze, cough and struggle to breathe.